We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QLYS icon
1
Qualys
QLYS
$5.61B
$10.4M 2.57%
117,187
-5,616
-5% -$505K
TIF
2
DELISTED
Tiffany & Co.
TIF
$9.35M 2.3%
72,500
– –
HDP
3
DELISTED
Hortonworks, Inc.
HDP
$9.34M 2.29%
409,408
-30,176
-7% -$629K
CW icon
4
Curtiss-Wright
CW
$26.1B
$7.91M 1.94%
57,526
-2,931
-5% -$384K
ADAP
5
DELISTED
Adaptimmune Therapeutics
ADAP
$7.67M 1.88%
+565,271
New +$5.93M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$7.16M 1.76%
+125,020
New +$6.14M
TMO icon
7
Thermo Fisher Scientific
TMO
$198B
$6.89M 1.69%
28,244
-1,916
-6% -$441K
PYPL icon
8
PayPal
PYPL
$49.9B
$6.88M 1.69%
78,300
-6,277
-7% -$553K
ROK icon
9
Rockwell Automation
ROK
$51.4B
$6.46M 1.59%
34,430
-2,816
-8% -$504K
PFPT
10
DELISTED
Proofpoint, Inc.
PFPT
$6.46M 1.59%
60,706
-4,349
-7% -$506K
TRMB icon
11
Trimble
TRMB
$12.3B
$6.17M 1.52%
141,992
-9,724
-6% -$380K
DAR icon
12
Darling Ingredients
DAR
$10B
$5.86M 1.44%
303,424
-24,405
-7% -$481K
KSU
13
DELISTED
Kansas City Southern
KSU
$5.74M 1.41%
50,653
-3,439
-6% -$392K
ANET icon
14
Arista Networks
ANET
$212B
$5.69M 1.4%
342,704
-20,304
-6% -$346K
FMC icon
15
FMC
FMC
$1.4B
$5.64M 1.39%
74,620
-3,880
-5% -$292K
PWR icon
16
Quanta Services
PWR
$94.3B
$5.63M 1.38%
168,553
-14,427
-8% -$491K
CSL icon
17
Carlisle Companies
CSL
$14B
$5.38M 1.32%
44,148
-3,573
-7% -$436K
LH icon
18
Labcorp
LH
$23.2B
$5.28M 1.3%
35,415
-2,506
-7% -$381K
IMPV
19
DELISTED
Imperva, Inc.
IMPV
$5.09M 1.25%
109,507
-9,441
-8% -$457K
AVNT icon
20
Avient
AVNT
$3.39B
$5.07M 1.25%
116,028
-8,099
-7% -$354K
ST icon
21
Sensata Technologies
ST
$6.55B
$4.98M 1.22%
100,545
-7,575
-7% -$397K
GRA
22
DELISTED
W.R. Grace & Co.
GRA
$4.98M 1.22%
69,665
-5,600
-7% -$404K
FSS icon
23
Federal Signal
FSS
$7.11B
$4.84M 1.19%
180,903
-13,634
-7% -$345K
CRS icon
24
Carpenter Technology
CRS
$27.7B
$4.73M 1.16%
80,189
-6,372
-7% -$365K
HOLX
25
DELISTED
Hologic
HOLX
$4.57M 1.12%
111,582
-9,202
-8% -$372K
1
2 3 4 5

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.